Bristol Myers Squibb taps Harbour BioMed in $1.1B-plus multispecific antibody pact
Bristol Myers Squibb has struck a multi-year, global strategic collaboration and license agreement with Harbour BioMed, deepening its push into next-generation antibody engineering as competition intensifies in immunology and oncology.
The agreement signed this morning granted Harbour BioMed up to $90 million in upfront and near-term payments, with additional development and commercial milestones totalling up to $1.035 billion, plus tiered royalties if Bristol Myers Squibb elects to advance all resulting programs.
The collaboration centres on the discovery and development of multi-specific antibodies, a modality increasingly viewed as a key lever for differentiation beyond traditional monoclonals.
The partnership will leverage Harbour BioMed’s Harbour Mice® fully human antibody platform, which is designed to accelerate the generation of complex antibody formats with improved specificity and therapeutic potential. While specific targets were not disclosed, the deal structure suggests a portfolio-style collaboration rather than a single-asset bet, allowing BMS to selectively advance programs as data emerge.
The agreement aligns with a broader strategy of externalising early discovery risk while securing optionality in high-complexity biologics. Multispecific antibodies capable of engaging multiple targets or immune pathways simultaneously are increasingly central to next-wave immunology and oncology strategies, particularly as first-generation checkpoint and cytokine approaches face saturation.
Harbour BioMed also brings a geographic advantage. The company highlighted the potential to conduct early-stage clinical trials in China, offering a pathway to accelerate proof-of-concept timelines and reduce development costs, an approach that has gained traction among global pharma partners seeking operational flexibility.
Related news
Zealand, OTR Sign Up to $2.5B Metabolic Drug Deal
The deal reinforces a continuing trend of Western pharma partnering with China-rooted biotechs not just for cost efficiency, but for differentiated platforms capable of generating globally competitive assets. The collaboration validates its technology at scale while preserving long-term upside through milestones and royalties rather than asset divestment.
As year-end dealmaking accelerates, the BMS–Harbour BioMed pact adds to a growing list of platform-driven collaborations, signalling that multispecific antibodies remain a priority area for big pharma pipeline renewal heading into 2026.
